AGTC:NSD-Applied Genetic Technologies Corporation (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 5.91

Change

-0.52 (-8.09)%

Market Cap

USD 0.15B

Volume

0.48M

Average Target Price

USD 13.00 (+119.97%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. The company's advanced product candidates consist of three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials. The company also has initiated one preclinical program in otology and three preclinical programs in targeting central nervous system disorders, including one in adrenoleukodystrophy. Applied Genetic Technologies Corporation has collaboration agreements with Synpromics Limited and University of Florida; Bionic Sight, LLC; and Otonomy, Inc. The company was founded in 1999 and is headquartered in Alachua, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-07-06 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+0.21 (+0.07%)

USD75.50B 48.39 36.24
REGN Regeneron Pharmaceuticals, Inc

+4.80 (+0.77%)

USD62.07B 30.02 20.75
SGEN Seattle Genetics, Inc

+1.42 (+0.84%)

USD29.51B N/A N/A
ALXN Alexion Pharmaceuticals, Inc

+1.27 (+1.13%)

USD25.08B 10.60 9.11
INCY Incyte Corporation

+1.32 (+1.24%)

USD22.68B 47.64 35.20
MRNA Moderna, Inc

+0.58 (+0.99%)

USD21.96B N/A N/A
BMRN BioMarin Pharmaceutical Inc

+0.93 (+0.73%)

USD21.81B 193.21 115.90
GMAB Genmab A/S

+0.82 (+2.45%)

USD21.51B 59.03 6.26
ALNY Alnylam Pharmaceuticals, Inc

+2.56 (+1.71%)

USD17.42B N/A N/A
BGNE BeiGene, Ltd

+0.86 (+0.44%)

USD15.19B N/A N/A

ETFs Containing AGTC

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 30.75% 70% C- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 30.75% 70% C- 82% B-
Trailing 12 Months  
Capital Gain 56.35% 74% C 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.35% 74% C 86% B
Trailing 5 Years  
Capital Gain -68.36% 38% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -68.36% 37% F 16% F
Average Annual (5 Year Horizon)  
Capital Gain -19.12% 17% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.12% 17% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 44.88% 64% D 37% F
Risk Adjusted Return -42.60% 16% F 9% F
Market Capitalization 0.15B 35% F 38% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 36.38 24% F 27% F
Price/Book Ratio 1.95 83% B 53% F
Price / Cash Flow Ratio -6.49 51% F 77% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -48.41% 69% D+ 25% F
Return on Invested Capital -4.98% 88% B+ 35% F
Return on Assets -26.58% 56% F 16% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 5.02 34% F 23% F
Short Percent 7.22% 42% F 30% F
Beta 2.69 8% F 5% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.